Metastatic castration-resistant prostate adenocarcinoma
Clinical trials for Metastatic castration-resistant prostate adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new Metastatic castration-resistant prostate adenocarcinoma trials appear
Sign up with your email to follow new studies for Metastatic castration-resistant prostate adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test could tell doctors when to stop prostate cancer treatment early
Disease control Recruiting nowThis study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the r…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA
Phase 1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests whether adding an immune-boosting vaccine (Sipuleucel-T) to a radioactive drug (Lu-PSMA) is safe and works better than the radioactive drug alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC